Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NYSE: TAK) | Delayed: 20.25 -0.11 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.36 | 52 Week High | $0.55 | |||
| Open | $20.28 | 52 Week Low | $0.55 | |||
| Day High | $20.39 | P/E | N/A | |||
| Day Low | $20.17 | EPS | $-0.20 | |||
| Volume | 1,698,428 | |||||
